Experts review groundbreaking insights from review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) and discuss the paradigm shift in myeloma frontline treatments, exploring quads, bispecifics, and the dynamic evolution of therapeutic approaches.
Mirna Chehade, MD, MPH, discusses the challenges faced by patients with eosinophilic esophagitis (EoE), including the absence of predictive factors for personalized treatment, the social implications of dietary restrictions, and the need for invasive procedures, while emphasizing the importance of regularly scheduled follow-up visits to address medical, nutritional, and psychosocial factors for better outcomes.
Health care professionals review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) multiple myeloma revelations, spotlighting transformative trials, groundbreaking translational research, and clinical perspectives that illuminate the evolving treatment landscape.
Experts discuss the evolving landscape of multiple myeloma treatment, exploring real-world evidence's role in shaping the future and its impact on clinical decisions, rare subgroups, and treatment sequencing.
Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.
Safety considerations for BTKi use in CLL and SLL treatment are highlighted.
Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL.
An expert ophthalmologist discusses a medication which targets enzymes in the Demodex mite, given over a six-week course.
Neda Shamie, MD, summarizes the prevalence and clinical manifestations of Demodex Blepharitis.
Experts discuss the role of multidisciplinary teams, gene expression patterns, rare disease drug designation, and education gaps in managing desmoid tumors, emphasizing the need for comprehensive care and precision medicine.
Aaron Gerds, MD, MS, explores myelofibrosis risk assessment, treatment goals, and therapeutic strategies, including JAK (Janus kinase inhibitors) inhibitors and transplant considerations.
Experts discuss the controversial role of gene expression patterns in desmoid tumor treatment decisions, highlighting challenges and potential impact on personalized care.
Dr Fonesca provides his final thoughts recapping data and findings presented at ASH 2023.
Dr Fonesca highlights key factors in multiple myeloma treatment affecting patient quality of life.
A key opinion leader explores the integration of bispecifics into MM therapy regimens.
The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.
The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.
A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.
Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.
Key opinion leaders explore the necessary synergy between payors and providers for optimizing bispecific therapy.
Financial considerations in bispecific therapy are discussed.
The critical impact of respiratory and physical therapists in the management of bronchiectasis is emphasized.
Amy Nguyen Howell, MD, MBA, outlines vital initiatives and resources to address health disparities in diabetic macular edema care, emphasizing unconscious bias training, CDC resources, academic courses, and collaborative advocacy efforts for promoting health equity.
Experts discuss findings from real-world studies comparing DRd with VRD, emphasizing the importance of individualized dosing and supportive care, and navigate challenges in incorporating real-world data.
Mirna Chehade, MD, MPH, discusses the impact of adverse events on influencing treatment decisions for eosinophilic esophagitis (EoE) in pediatric patients, and considerations for the use of biologics.
Renowned multiple myeloma specialists discuss challenges in treatment decisions, exploring real-world data's role, assessing risks in diverse populations, and interpreting cross-trial comparisons.
Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.
A panel of experts discuss leveraging real-world data in multiple myeloma treatment decisions and explore the significance, limitations, and evolving role of real-world data, shedding light on patient experiences, access to care, and treatment outcomes beyond clinical trials.
Richard Adler, MD, FACS, provides perspective on AAO 2023 data suggesting dual mechanism treatment targeting aqueous deficiency and meibomian gland dysfunction may improve dry eye symptoms more significantly and faster than singular therapies, benefiting patient compliance and disease management.
Richard Adler, MD, FACS, provides insights on data presented at AA0 2023, from a study comparing results of the ARMOR procedure versus treatment with cyclosporine ophthalmic emulsion 0.05% in patients with dry eye disease.
